Molecular testing in early breast cancer: Perspectives from a surgeon, radiation and medical oncologists
Supported by Lilly
Tuesday, October 19, 2021
20:00 (8:00PM) (AEST)
|Chairperson||Frances Boyle, Sydney, Australia|
|20:00-20:05|| Welcome & Introduction
Frances Boyle, Sydney, Australia
|20:05-20:17||Selecting Patients with Luminal Tumours for Neoadjuvant chemotherapy
Andrew Spillane, Sydney, Australia
|20:22-20:34||Predicting the risk of recurrence in ER+ve early breast cancer: when and how do genomic assays help in our decision making?
Belinda Yeo, Melbourne, Australia
|20:39-20:46||The Clinical Utility of Genomic Assays on Radiation Therapy Decision Making in DCIS and Early Breast Cancer
Gillian Lamoury, Sydney, Australia
|20:50-21:00||Summary & Close
Frances Boyle, Sydney, Australia
MEET THE FACULTY
|Fran Boyle, Australia||Gillian Lamoury, Australia||Andrew Spillane, Australia||Belinda Yeo, Australia|
Fran Boyle is a Medical Oncologist at North Sydney’s Mater Hospital, where she is Director of the Patricia Ritchie Centre for Cancer Care and Research, and Professor of Medical Oncology at the University of Sydney. She is a member of the Scientific Advisory committees of BCT and IBCSG and has been involved in all facets of clinical trial research in breast cancer.
Associate Professor of Surgical Oncology
Andrew Spillane is Professor of Surgical Oncology at The University of Sydney, Northern Clinical School. He specialises in the surgical management of breast cancer and melanoma. Andrew is a senior VMO surgeon at the Mater North Sydney, Royal North Shore Hospital and North Shore Private Hospitals.
Andrew is a member of the BCT Board and Scientific Advisory Committee. He is past President of BreastSurgANZ and a board member / Deputy Chair of Melanoma and Skin Cancer (MASC) Trials (formerly the ANZMTG). Andrew is Breast sub-editor for the ANZ Journal of Surgery, and founding co-director of the University of Sydney’s Graduate Certificate in Advanced Breast Surgery.
Dr Belinda Yeo (FRACP, MD, MBBS, BA)
Belinda Yeo is jointly appointed to the Austin Hospital in Melbourne, Australia, as a Medical Oncologist and to the Olivia Newton-John Cancer Research Institute as a Clinician Scientist with a specific interest in breast cancer. She trained in Sydney before joining the Breast Unit at The Royal Marsden Hospital, London as a Clinical and Research Fellow. She completed a Master’s Degree at The University of London and The Institute of Cancer Research in novel genomic and non-molecular breast cancer risk assays. She is co-lead of the VCCC Research and Education Stream for Breast Cancer, she is a clinical trial investigator and continues her translational research investigating improving personalization and minimising toxicities for patients with breast cancer.
A/Prof Gillian Lamoury
Gillian is a specialist Radiation Oncologist at the Northern Sydney Cancer Centre, with a sub-speciality interest in the treatment of breast cancer.
She is Clinical Associate Professor at the University of Sydney, and a Visiting Medical officer (VMO) in Radiation Oncology at the Mater Hospital, North Sydney.
She completed postgraduate study at St Vincent’s Hospital/ Garvan Research Institute in the molecular sub-typing of breast cancer, after obtaining her Fellowship from the Faculty of Radiation Oncology.Gillian is the recent Chair of the Breast Cancer Advisory Group (BCAG) for Cancer Australia (2018-2020)
Gillian advocates for better patient care through her work with several strategic groups. She’s the inaugural Chair of the Breast Interest Group Faculty of Radiation Oncology (BIG-FRO 2014), a member of the Australasian Society of Breast Disease, and the ANZ Breast Cancer Trials Group (BCT). She is also a member of the Strategic Advisory Group for Breast Cancer Network Australia (BCNA),
Gillian is actively involved in quality assurance programs and research at the Northern Sydney Cancer Centre where she is is Principal Investigator on several innovative breast cancer trials.
Gillian is passionate about patient-centred care and the delivery of state-of-the-art and innovative radiotherapy techniques for breast cancer.
She strives to provide the highest quality of compassionate and evidence-based care for all her patients.Her philanthropic interests and passion for equitable access to high quality cancer treatments have led to her accepting a position on the Board of the GenesisCare Foundation (2020).